Back to top
more

Medtronic (MDT)

(Real Time Quote from BATS)

$91.63 USD

91.63
1,878,933

-1.11 (-1.20%)

Updated Aug 12, 2025 01:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Tandem Rides on Strong t:slim X2 Rollout Amid Stiff Rivalry

by Zacks Equity Research

Tandem Diabetes (TNDM) gains on strong domestic sales along with a solid international rollout of the t:slim X2 insulin pump.

Zacks Equity Research

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) raises 2019 revenue and earnings per share guidance.

Zacks Equity Research

QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits

by Zacks Equity Research

The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area

Urmimala Biswas headshot

Align Rides on Volume Expansion Amid Poor Shipment Scenario

by Urmimala Biswas

Align Technology (ALGN) is continuing with its winning streak of delivering a sturdy Invisalign Technology volume expansion across the company's entire customer base.

Zacks Equity Research

Edwards Lifesciences Hits a 52-Week High on Solid Prospects

by Zacks Equity Research

Edwards Lifesciences (EW) has been consistently delivering impressive results.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock Now

by Zacks Equity Research

Investor confidence is still high on Henry Schein (HSIC), thanks to solid prospects.

Zacks Equity Research

Medtronic (MDT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Medtronic (MDT) closed at $107.42 in the latest trading session, marking a +0.63% move from the prior day.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) to Your Portfolio Now

by Zacks Equity Research

Stryker's (SYK) core Mako Platform has been consistently driving its top line.

Zacks Equity Research

4 Stocks From Highest Job-Creating Sectors in September

by Zacks Equity Research

Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.

Urmimala Biswas headshot

Medtronic Submits Two Pelvic Health Devices for FDA's PMA

by Urmimala Biswas

Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.

Zacks Equity Research

Stratasys Unveils Medical 3D Printer, Boosts Market Foothold

by Zacks Equity Research

Stratasys' (SSYS) new 3D printer is especially beneficial for medical device companies, which require new ways to drive faster adoption of technologies and procedures.

Zacks Equity Research

Medtronic Gets FDA's Breakthrough Device Nod for Valiant TAAA

by Zacks Equity Research

This FDA designation is expected to bolster Medtronic's (MDT) Aortic, Peripheral & Venous line within the broader Cardiac and Vascular group.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock Now

by Zacks Equity Research

Investor confidence is still high on Teleflex (TFX), thanks to solid prospects.

Zacks Equity Research

Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study

by Zacks Equity Research

Axonics (AXNX) expects to improve performance on the positive outcome of the study.

Zacks Equity Research

Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Medtronic (MDT) closed at $106.93, marking a +0.93% move from the previous day.

Zacks Equity Research

Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds

by Zacks Equity Research

Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).

Zacks Equity Research

Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod

by Zacks Equity Research

Abiomed's (ABMD) flagship Impella heart pump line is a major growth driver.

Zacks Equity Research

Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT

by Zacks Equity Research

Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.

Zacks Equity Research

Here's Why You Should Hold on to Quest Diagnostics Stock Now

by Zacks Equity Research

Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.

Zacks Equity Research

Illumina, Broad Institute Partner on Secondary Genomic Analysis

by Zacks Equity Research

The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Comcast, Nike, Medtronic and salesforce.com

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Comcast, Nike, Medtronic and salesforce.com

Zacks Equity Research

Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System

by Zacks Equity Research

The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.

Zacks Equity Research

Medtronic's All Business Lines Grow Despite Cost Concerns

by Zacks Equity Research

Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.

Zacks Equity Research

Has Medtronic (MDT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (MDT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Varian, Stryker and Medtronic

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Varian, Stryker and Medtronic